News
02-15-2013, 03:21 AM
An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in one of the most difficult-to-treat forms of cancer -- high-risk triple-negative breast cancer. The median survival for metastatic triple-negative breast cancer patients is historically nine months...
More... (http://www.medicalnewstoday.com/releases/256375.php)
More... (http://www.medicalnewstoday.com/releases/256375.php)